Shakiba et al. reported consistent findings in a 4T1 murine breast cancer model, where co-administration of Hes (20 mg/kg) and doxorubicin (10 mg/kg) yielded an 80% survival rate, elevated IFN-γ levels, and suppression of pro-angiogenic and proliferative markers (VEGFa, MMP9, Ki-67). Here, VEGFA is linked to breast carcinoma.